2 Drug Stocks Under Pressure This Morning

Retrophin is in the Nasdaq's cellar after dismal drug data

Managing Editor
Aug 22, 2019 at 10:12 AM
facebook twitter linkedin


Two biotech names under pressure this morning are Mustang Bio Inc (NASDAQ:MBIO) and Retrophin Inc (NASDAQ:RTRX). Below, we'll get in to what's caused each stock to make such outsized moves lower today.

First up is Mustang Bio, down 6% to trade at $4.36, despite the Food and Drug Administration (FDA) granting expedited review status to the company's experimental treatment for a rare genetic disorder, bubble boy disease. MBIO initially looked ready to build on yesterday's 14.8% gain, in aftermarket trading, but pivoted lower after the open, below its 320-day moving average, a trendline that stymied yesterday's rally.

Anyone looking for an explanation of the sudden pivot they could note that MBIO's 14-day Relative Strength Index (RSI) was running hot, coming in at 75 as of yesterday's close. In other words, the shares were due for a short-term breather.

Also swimming in red this morning is Retrophin stock, down 26.7% to trade at $12.75, and earlier falling to a three-year low of $11.84. This comes after the company's experimental treatment for pantothenate kinase-associated neurodegeneration (PKAN) failed its main goal of a late-stage trial. In response, BMO Capital trimmed its price target to $38 from $43.

This is pacing to be RTRX's worst single-session drop since December 2012. Even prior to today, the shares had shed 57% year-over-year, and saw a July breakout stymied by their 200-day moving average. Today's singular bear note could be a sign of things to come; all five in coverage of the equity rate it a "strong buy," and the consensus 12-month price target of $40.71 sits in territory not traded at since 2005.

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners